Dr. Haluska has served as BioCanCell’s CEO since October 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib, approved in the US by the FDA.
Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. He has also served as a flight surgeon in the U.S. Air Force, and continues to serve in the Massachusetts Air National Guard with the rank of Colonel.
Dr. Moore has more than 16 years of experience in the pharmaceutical industry, and has participated in four registration programs and five global drug launches.
Prior to joining BioCanCell, Dr. Moore served as the vice president of medical affairs at ARIAD Pharmaceuticals, where he was responsible for global medical affairs strategy, planning and execution. Prior to joining ARIAD, Dr. Moore served as a lead drug developer in three different global pharmaceutical companies (Sanofi, GSK, BMS) and held positions of growing responsibility (director to AVP). In addition, Dr. Moore served as the global head of medical affairs at GPC Biotech and as the global medical director of GU oncology at Oncura (a business unit of GE Healthcare).
Dr. Moore earned Bachelor of Science and MD degrees from the Sackler School of Medicine (Tel Aviv University, Israel), followed by training in internal medicine at the E. Wolfson Medical Center and in Ob/Gyn at the Meir Medical Center. In 2006, he received an MBA from the LeBow College of Business at Drexel University in Philadelphia.
Mr. Burgin has served as BioCanCell’s CFO and COO since October 2016, having previously served as CEO from 2012 to 2016, and as CFO from 2011 to 2012. From 2006 to 2011, he was CFO of Radcom, Ltd. (NASDAQ: RDCM), a service assurance provider, and CFO of XTL Biopharmaceuticals (TASE: XTL, NASDAQ: XTLB), a drug development company, from 1999 to 2006, where he took an active role in the process of listing its shares on the NASDAQ, London Stock Exchange and TASE, and in raising $113 million in four financing rounds. Between 1997 and 1999, he was CFO of YLR Capital Markets, a publicly-traded Israeli investment bank, and rose to become a Senior Manager at Kesselman & Kesselman, the Israeli member of PricewaterhouseCoopers International, Ltd, between 1984 and 1997. Mr. Burgin earned an M.B.A. and a B.A. in Accounting and Economics from Tel-Aviv University and is certified in Israel as a CPA.
Prof. Hochberg was BioCanCell’s Chief Scientist from its inception until his passing in October 2016. A biochemist and molecular biologist in the Department of Biological Chemistry at the Hebrew University of Jerusalem, Prof. Hochberg was recognized as a world-leading expert on the H19 gene, which plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions. He led the decades-long ground-breaking research that led to the development of BC-819. Prof. Hochberg’s list of approximately 140 publications covers seminal contributions in the fields of imprinted genes, the H19 gene, the IGF2 gene and oncology. He held a Ph.D. in the natural sciences, and a B.Sc. in Archeology.